Related references
Note: Only part of the references are listed.Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
Geoffrey Shapiro et al.
INVESTIGATIONAL NEW DRUGS (2020)
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
Ryan J. Sullivan et al.
MOLECULAR CANCER THERAPEUTICS (2020)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
Andrea Varga et al.
CLINICAL CANCER RESEARCH (2020)
Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling
Paul Dent et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Jenny Y. Xue et al.
NATURE (2020)
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
M. D. Hellmann et al.
ANNALS OF ONCOLOGY (2019)
Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer
Elaine Lai-Han Leung et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Kirsten L. Bryant et al.
NATURE MEDICINE (2019)
Genomic correlates of response to immune checkpoint blockade
Tanya E. Keenan et al.
NATURE MEDICINE (2019)
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
Conan G. Kinsey et al.
NATURE MEDICINE (2019)
A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma
Alain Patrick Algazi et al.
PIGMENT CELL & MELANOMA RESEARCH (2019)
Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds
Abimael Cruz-Migoni et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction
Roman C. Hillig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
RIT1 oncoproteins escape LZTR1-mediated proteolysis
Pau Castel et al.
SCIENCE (2019)
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF
Maria Teresa Blasco et al.
CANCER CELL (2019)
A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts).
Shubham Pant et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.
Tae Won Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
Hengyu Lu et al.
MOLECULAR CANCER THERAPEUTICS (2019)
KRASG12C inhibition produces a driver-limited state revealing collateral dependencies
Kevin Lou et al.
SCIENCE SIGNALING (2019)
Endogenous CD4+ thorn T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 (Her2) Driver Mutations
Joshua R. Veatch et al.
CANCER IMMUNOLOGY RESEARCH (2019)
A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia
Nagore I. Marin-Ramos et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Ryan J. Sullivan et al.
NATURE MEDICINE (2019)
Drugging an undruggable pocket on KRAS
Dirk Kessler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial
Eileen M. O'Reilly et al.
JAMA ONCOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Miriam Molina-Arcas et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis
Dana Rabara et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers
Rita Sulahian et al.
CELL REPORTS (2019)
Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology
Matthias Gehringer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Targeting the α4-α5 dimerization interface of K-RAS inhibits tumor formation in vivo
Imran Khan et al.
ONCOGENE (2019)
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
Ulrich Keilholz et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Ryan J. Sullivan et al.
CANCER DISCOVERY (2018)
c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling
Manuel Sanclemente et al.
CANCER CELL (2018)
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
Chiara Ambrogio et al.
CELL (2018)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
Rce1: mechanism and inhibition
Shahienaz E. Hampton et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2018)
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
Eric Van Cutsem et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Preliminary Results From a Phase 2 Trial of Tipifarnib in HRAS-Mutant Head and Neck Squamous Cell Carcinomas
A. Ho et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors
Yuanyuan Xie et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Dietrich A. Ruess et al.
NATURE MEDICINE (2018)
Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
M. A. Socinski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Afatinib restrains K-RAS-driven lung tumorigenesis
Herwig P. Moll et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
The ERBB network facilitates KRAS-driven lung tumorigenesis
Bjorn Kruspig et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
Sobhana Babu Boga et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1-and RAS-driven cancers
Robert J. Nichols et al.
NATURE CELL BIOLOGY (2018)
Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
Camilo E. Quevedo et al.
NATURE COMMUNICATIONS (2018)
Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors
Ivana Yen et al.
CANCER CELL (2018)
SHOC2-MRAS-PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis
Lucy C. Young et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
Stergios J. Moschos et al.
JCI INSIGHT (2018)
Inhibition of K-RAS4B by a Unique Mechanism of Action: Stabilizing Membrane-Dependent Occlusion of the Effector-Binding Site
Zhenhao Fang et al.
CELL CHEMICAL BIOLOGY (2018)
Inhibition of RAS function through targeting an allosteric regulatory site
Russell Spencer-Smith et al.
NATURE CHEMICAL BIOLOGY (2017)
LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
Eliza Vakana et al.
ONCOTARGET (2017)
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Matthew A. Coelho et al.
IMMUNITY (2017)
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors
Monica Mita et al.
INVESTIGATIONAL NEW DRUGS (2017)
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer The SELECT-1 Randomized Clinical Trial
Pasi A. Janne et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Spatiotemporal Analysis of K-Ras Plasma Membrane Interactions Reveals Multiple High Order Homo-oligomeric Complexes
Suparna Sarkar-Banerjee et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Inhibition of Isoprenylcysteine Carboxylmethyltransferase Induces Cell-Cycle Arrest and Apoptosis through p21 and p21-Regulated BNIP3 Induction in Pancreatic Cancer
Kanjoormana Aryan Manu et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS
Sarah J. Ross et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
Mark Merchant et al.
PLOS ONE (2017)
A phase VII trial of TG01/GM-CSF and gemcitabine as adjuvant therapy for treating patients with resected RAS-mutant adenocarcinoma of the pancreas.
Daniel H. Palmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ras Binder Induces a Modified Switch-II Pocket in GTP and GDP States
Daniel R. Gentile et al.
CELL CHEMICAL BIOLOGY (2017)
Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition
Rona Yaeger et al.
CANCER RESEARCH (2017)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
A. Gordon Robertson et al.
CELL (2017)
Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations
Yung-mae M. Yao et al.
CLINICAL CANCER RESEARCH (2017)
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
Andrew J. Aguirre et al.
CANCER CELL (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras
Tim Wang et al.
CELL (2017)
Multivalent Small-Molecule Pan-RAS Inhibitors
Matthew E. Welsch et al.
CELL (2017)
Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors
Qiong J. Wang et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: a controlled, open-label phase II trial with crossover
C. Lebbe et al.
ANNALS OF ONCOLOGY (2016)
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer
C. A. Carter et al.
ANNALS OF ONCOLOGY (2016)
8-Hydroxyquinoline-based inhibitors of the Rce1 protease disrupt Ras membrane localization in human cells
Idrees Mohammed et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
Eva Segelov et al.
BMC CANCER (2016)
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling (vol 30, pg 485, 2016)
Zoi Karoulia et al.
CANCER CELL (2016)
Negative feedback regulation of the ERK1/2 MAPK pathway
David Lake et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors
Geoffrey Richard et al.
EMBO MOLECULAR MEDICINE (2016)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Ying-Nan P. Chen et al.
NATURE (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Eric Tran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Piro Lito et al.
SCIENCE (2016)
Coincident signals from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3Kβ in myeloid cells
Daniel M. Houslay et al.
SCIENCE SIGNALING (2016)
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
Matthew P. Patricelli et al.
CANCER DISCOVERY (2016)
EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma
Hsuan-Yu Chen et al.
ONCOTARGET (2016)
Coincident signals from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3Kβ in myeloid cells
Daniel M. Houslay et al.
SCIENCE SIGNALING (2016)
A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma.
Alexander Noor Shoushtari et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
G. R. Blumenschein et al.
ANNALS OF ONCOLOGY (2015)
Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma
Brian A. Boone et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Ras nanoclusters: Versatile lipid-based signaling platforms
Yong Zhou et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2015)
Inhibition of RAF lsoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Sheng-Bin Peng et al.
CANCER CELL (2015)
Genomic Classification of Cutaneous Melanoma
Rehan Akbani et al.
CELL (2015)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
Douglas B. Johnson et al.
EUROPEAN JOURNAL OF CANCER (2015)
Small Molecule Binding Sites on the Ras:SOS Complex Can Be Exploited for Inhibition of Ras Activation
Jon J. G. Winter et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
John C. Hunter et al.
MOLECULAR CANCER RESEARCH (2015)
Comprehensive genomic characterization of head and neck squamous cell carcinomas
Michael S. Lawrence et al.
NATURE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site
Mohammad T. Mazhab-Jafari et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices
Elizaveta S. Leshchiner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway
Xiaolin Nan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif
Frederick D. Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
GTP-Dependent K-Ras Dimerization
Serena Muratcioglu et al.
STRUCTURE (2015)
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
Talia Golan et al.
ONCOTARGET (2015)
Specific cancer-associated mutations in the switch III region of Ras increase tumorigenicity by nanocluster augmentation
Maja Solman et al.
ELIFE (2015)
A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors
A. W. Tolcher et al.
ANNALS OF ONCOLOGY (2015)
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
Anthony W. Tolcher et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
Philippe L. Bedard et al.
CLINICAL CANCER RESEARCH (2015)
Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
Piro Lito et al.
CANCER CELL (2014)
Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS-RAF Mutations
Lisa Zimmer et al.
CLINICAL CANCER RESEARCH (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics
Apirat Chaikuad et al.
NATURE CHEMICAL BIOLOGY (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Ras signaling is essential for skin development
M. Drosten et al.
ONCOGENE (2014)
Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma
Brian M. Wolpin et al.
ONCOLOGIST (2014)
Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance
Phillip A. Schwartz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
H-Ras forms dimers on membrane surfaces via a protein-protein interface
Wan-Chen Lin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
Michael C. Burns et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations
Annan Yang et al.
CANCER DISCOVERY (2014)
Mutation-Specific RAS Oncogenicity Explains NRAS Codon 61 Selection in Melanoma
Christin E. Burd et al.
CANCER DISCOVERY (2014)
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
Chong Sun et al.
CELL REPORTS (2014)
A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.
Dejan Juric et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The RASopathies
Katherine A. Rauen
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, VOL 14 (2013)
A Switch in the Expression of Embryonic EMT-Inducers Drives the Development of Malignant Melanoma
Julie Caramel et al.
CANCER CELL (2013)
Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma
Akito Nakamura et al.
CANCER RESEARCH (2013)
Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
Muling Mao et al.
CLINICAL CANCER RESEARCH (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Inflammatory networks and immune surveillance of pancreatic carcinoma
Robert H. Vonderheide et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab
Marc Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives
Masanori Okaniwa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Cory M. Johannessen et al.
NATURE (2013)
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling
Gunther Zimmermann et al.
NATURE (2013)
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
Georgia Hatzivassiliou et al.
NATURE (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 Kinase in KRAS-Mutant Lung Cancer
Miriam Molina-Arcas et al.
CANCER DISCOVERY (2013)
A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
Steven R. Whittaker et al.
CANCER DISCOVERY (2013)
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
Erick J. Morris et al.
CANCER DISCOVERY (2013)
Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
Jessie Villanueva et al.
CELL REPORTS (2013)
Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation
Qi Sun et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
N-Ras Forms Dimers at POPC Membranes
Joern Gueldenhaupt et al.
BIOPHYSICAL JOURNAL (2012)
EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma
Carolina Navas et al.
CANCER CELL (2012)
EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis
Christine M. Ardito et al.
CANCER CELL (2012)
Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
Klaus P. Hoeflich et al.
CANCER RESEARCH (2012)
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
Gyoergy Bodoky et al.
INVESTIGATIONAL NEW DRUGS (2012)
Conformation-Specific Effects of Raf Kinase Inhibitors Miniperspective
Xiaolun Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
Georgia Hatzivassiliou et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale et al.
NATURE (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins
Anchal Chandra et al.
NATURE CELL BIOLOGY (2012)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity
Till Maurer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Receptor Tyrosine Kinases and TLR/IL1 Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression
Michael C. Schmid et al.
CANCER CELL (2011)
Pancreatic cancers require autophagy for tumor growth
Shenghong Yang et al.
GENES & DEVELOPMENT (2011)
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
Jaafar Bennouna et al.
INVESTIGATIONAL NEW DRUGS (2011)
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
Hiromichi Ebi et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Discovery and SAR of Methylated Tetrahydropyranyl Derivatives as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase (ICMT)
Weston R. Judd et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
An orthosteric inhibitor of the Ras-Sos interaction
Anupam Patgiri et al.
NATURE CHEMICAL BIOLOGY (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
Matthias Drosten et al.
EMBO JOURNAL (2010)
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens
John D. Hainsworth et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies
Chen Mao et al.
LUNG CANCER (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Inhibition of isoprenylcysteine carboxylmethyltransferase induces autophagic-dependent apoptosis and impairs tumor growth
M. Wang et al.
ONCOGENE (2010)
Ras membrane orientation and nanodomain localization generate isoform diversity
Daniel Abankwa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Susan Wee et al.
CANCER RESEARCH (2009)
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Caroline M. Emery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
Christine A. Pratilas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
BRAF V600E disrupts AZD6244-Induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins
Bret B. Friday et al.
CANCER RESEARCH (2008)
The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway
Marie Dance et al.
CELLULAR SIGNALLING (2008)
Palmitoylation and localisation of RAS isoforms are modulated by the hypervariable linker domain
Alex J. Laude et al.
JOURNAL OF CELL SCIENCE (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents:: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
Helena Linardou et al.
LANCET ONCOLOGY (2008)
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
Kevin M. Haigis et al.
NATURE GENETICS (2008)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Partial functional overlap of the three ras genes in mouse embryonic development
K. Nakamura et al.
ONCOGENE (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Plasma membrane nanoswitches generate high-fidelity Ras signal transduction
Tianhai Tian et al.
NATURE CELL BIOLOGY (2007)
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma
Barbara A. Frederick et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases
D. M. Owens et al.
ONCOGENE (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Sprouty proteins: multifaceted negative-feed back regulators of receptor tyrosine kinase signaling
JM Mason et al.
TRENDS IN CELL BIOLOGY (2006)
H-ras, K-ras, and inner plasma membrane raft proteins operate in nanoclusters with differential dependence on the actin cytoskeleton
SJ Plowman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition
S Thomson et al.
CANCER RESEARCH (2005)
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
LA Garraway et al.
NATURE (2005)
Replacement of K-Ras with H-Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice
N Potenza et al.
EMBO REPORTS (2005)
A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells
AM Winter-Vann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Regulation of raf-1 by direct feedback phosphorylation
MK Dougherty et al.
MOLECULAR CELL (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Modulation of signalling by sprouty: A developing story
HJ Kim et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Direct visualization of Ras proteins in spatially distinct cell surface microdomains
IA Prior et al.
JOURNAL OF CELL BIOLOGY (2003)
While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable
SJ Plowman et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
ME Dudley et al.
SCIENCE (2002)
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
M Tartaglia et al.
NATURE GENETICS (2001)
Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant:: Clinical and immunological responses in patients with pancreatic adenocarcinoma
MK Gjertsen et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation
E Hirsch et al.
SCIENCE (2000)
Formation of the Ras dimer is essential for Raf-1 activation
K Inouye et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity
ZQ Shi et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Share Paper
